249 filings
Page 4 of 13
6-K
aoa7n77l
17 Jun 22
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
4:15pm
6-K
0augex6
17 May 22
Current report (foreign)
9:08am
6-K
74vxkhc nhaad
17 May 22
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
8:20am
6-K
86n7 eicdv
17 May 22
Galmed updates business and clinical development strategy to better leverage Aramchol’s anti-fibrotic effects
7:51am
6-K
d64o qlmd02le2vu
2 May 22
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial
7:07am
6-K
5d5nd
28 Apr 22
Current report (foreign)
8:04am
6-K
k3i7q
3 Mar 22
Current report (foreign)
5:16pm
6-K
6r976 moj86lkmko
11 Jan 22
Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt
8:15am
6-K
oey aadl10qh50vw7
10 Jan 22
Galmed announces positive results of Phase 1 study of Amilo-5MER
8:11am
6-K
thcqt0ql gfpwdt3
8 Nov 21
Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results
8:25am
6-K
pst5y
1 Nov 21
Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
10:23am
6-K
mrr2lltiea56ev8
12 Oct 21
Results of Galmed’s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine
7:00am
6-K
nn8gj9dtjxdf3axsh0
31 Aug 21
Current report (foreign)
4:30pm
6-K
gtdm egny
23 Aug 21
Current report (foreign)
4:30pm
6-K
r3sttty
19 Aug 21
Galmed Pharmaceuticals Announces Publication in “The Journal of Autoimmunity” for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
8:11am
6-K
eqqg9 wlofx
16 Aug 21
MHRA Agrees with Galmed’s Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study
8:31am
6-K
eztt2sc479uxmmwofsn
5 Aug 21
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
7:00am
6-K
g5fkc2s60mn
2 Aug 21
FDA Agrees with Galmed’s Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
7:47am
6-K
f5fwc3b5l
19 Jul 21
Current report (foreign)
4:30pm